United Therapeutics (UTHR) Short term Debt (2017 - 2025)

United Therapeutics has disclosed Short term Debt across 6 years of filings, most recently posting $200.0 million for Q1 2025.

• In Q1 2025, Short term Debt fell 50.0% year-over-year to $200.0 million; the TTM figure through Mar 2025 stood at $200.0 million (down 50.0% YoY), while the FY2024 annual figure was $300.0 million, down 25.0% from the prior year.
• Short term Debt came in at $200.0 million for Q1 2025 at United Therapeutics, down from $300.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $400.0 million in Q4 2023 to a low of $200.0 million in Q1 2025.
• Average Short term Debt over 3 years is $342.9 million, with a median of $400.0 million recorded in 2023.
• Year-over-year, Short term Debt surged 33.33% in 2024 and tumbled 50.0% in 2025.
• Over 3 years, Short term Debt stood at $400.0 million in 2023, then declined by 25.0% to $300.0 million in 2024, then slumped by 33.33% to $200.0 million in 2025.
• Per Business Quant data, the three most recent Short term Debt figures were $200.0 million in Q1 2025, $300.0 million in Q4 2024, and $400.0 million in Q3 2024.